(a).

Rank	Term	Count	Symbol	P value
1	hsa04110:Cell cycle	13	YWHAZ, CREBBP, TP53, PRKDC, RB1, CDK2, HDAC2, EP300, HDAC1, PCNA, MDM2, MYC, andCUL1	1.50E − 14
2	hsa05200:Pathways in cancer	11	TRAF2, EP300, HDAC2, HDAC1, CREBBP, TP53, MDM2, RB1, MYC, CDK2, and CTNNB1	3.51E − 07
3	hsa05215:Prostate cancer	7	EP300, CREBBP, TP53, MDM2, RB1, CDK2, and CTNNB1	1.45E − 06
4	hsa05220:Chronic myeloid leukemia	6	HDAC2, HDAC1, TP53, MDM2, RB1, and MYC	1.32E − 05
5	hsa04310:Wnt signaling pathway	6	EP300, CREBBP, TP53, MYC, CUL1, and CTNNB1	3.78E − 04
6	hsa05222:Small cell lung cancer	5	TRAF2, TP53, RB1, MYC, and CDK2	4.04E − 04
7	hsa05219:Bladder cancer	4	TP53, MDM2, RB1, and MYC	7.24E − 04
8	hsa04330:Notch signaling pathway	4	EP300, HDAC2, HDAC1, and CREBBP	0.001008
9	hsa04520:Adherens junction	4	EP300, CREBBP, SRC, and CTNNB1	0.00418
10	hsa04350:TGF-beta signaling pathway	4	EP300, CREBBP, MYC, and CUL1	0.005889
11	hsa05016:Huntington's disease	5	EP300, HDAC2, HDAC1, CREBBP, and TP53	0.006736
12	hsa05216:Thyroid cancer	3	TP53, MYC, and CTNNB1	0.00676
13	hsa04120:Ubiquitin mediated proteolysis	4	CUL3, MDM2, BRCA1, and CUL1	0.020254
14	hsa05213:Endometrial cancer	3	TP53, MYC, and CTNNB1	0.020793
15	hsa05214:Glioma	3	TP53, MDM2, and RB1	0.029762
16	hsa04115:p53 signaling pathway	3	TP53, MDM2, and CDK2	0.034267
17	hsa05218:Melanoma	3	TP53, MDM2, and RB1	0.037091
18	hsa05210:Colorectal cancer	3	TP53, MYC, and CTNNB1	0.050311
19	hsa04210:Apoptosis	3	TRAF2, IRAK1, and TP53	0.053574
20	hsa03450:Non-homologous end-joining	2	XRCC6and PRKDC	0.05487
21	hsa04916:Melanogenesis	3	EP300, CREBBP, and CTNNB1	0.067353
22	hsa04114:Oocyte meiosis	3	YWHAZ, CDK2, and CUL1	0.080913
23	hsa04722:Neurotrophin signaling pathway	3	IRAK1, YWHAZ, and TP53	0.099295

The significant pathways via DAVID Bioinformatics database are selected for the 152 significant proteins in carcinogenesis. Black background indicates P value > 0.05.